Chatelain P, Bertrand J, David M, Sassolas G, Catbeh N, Morel Y, Ruitton A, Ferry S, Gilly R, Philip T
Arch Fr Pediatr. 1985 Mar;42(3):205-9.
A single acute IV injection (1 microgram/kg) of the synthetic replicate of Somatocrinin (GRF) in 40 children with growth hormone (GH) deficiency induces a marked plasma GH increase, although heterogeneous. Clinical tolerance is excellent. Compared to Propranolol + Glucagon (P + G), GRF induces a better GH response. It also discriminates better idiopathic GH deficiency (n = 13), where mean GH peak = 6.5 ng/ml (3.3 after P + G) from GH deficiency secondary to a brain tumor (n = 24) where mean GH peak = 15.5 ng/ml (5.0 after P + G) GRF induces a slight Prolactin (Prl) increase, more obvious when basal Prl is elevated. However there is no correlation between GH and Prl responses to GRF even with basal hyperprolactinemia. GH response to GRF seems to slowly decrease after radiation therapy. GRF is a new potent, well tolerated secretagogue of GH and improves the diagnostic quality of the etiology of GH deficiency.
对40名生长激素(GH)缺乏的儿童单次静脉注射(1微克/千克)生长激素释放素(GRF)的合成复制品,可使血浆GH显著升高,尽管存在异质性。临床耐受性良好。与普萘洛尔+胰高血糖素(P+G)相比,GRF能诱导更好的GH反应。它还能更好地区分特发性GH缺乏(n = 13),其平均GH峰值为6.5纳克/毫升(P+G后为3.3)和继发于脑肿瘤的GH缺乏(n = 24),其平均GH峰值为15.5纳克/毫升(P+G后为5.0)。GRF会使催乳素(Prl)略有升高,当基础Prl升高时更为明显。然而,即使存在基础高催乳素血症,GH和Prl对GRF的反应之间也没有相关性。放疗后GH对GRF的反应似乎会缓慢下降。GRF是一种新型的、耐受性良好的GH促分泌剂,可提高GH缺乏病因诊断的质量。